Bailitiane announced that the Phase III clinical trial of the innovative biopharmaceutical BL-B01D1 (EGFR×HER3-ADC), independently developed by the company, for locally advanced or metastatic triple-negative breast cancer with unresectable lesions or prior treatment failure with taxanes, has successfully enrolled the first subject.
百利天恒：BL-B01D1用于三阴乳腺癌III期临床试验完成首例入组
Bailitianteng: BL-B01D1 completed the first phase III clinical trial entry for triple negative breast cancer.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.